Intellia Therapeutics, Inc. announces its strategic priorities for the upcoming two years as the Company enters its next phase of pipeline execution and platform innovation.
Among the 2023-2024 Strategic Priorities are to initiate global pivotal trials for Intellia’s investigational in vivo CRISPR-based therapy NTLA-2002 for HAE.
“2022 proved to be another outstanding year for Intellia, with several significant clinical milestones achieved across our pipeline, further reinforcing the ability of our modular CRISPR genome editing platform to target a broad range of diseases,” says Intellia President and CEO John Leonard, M.D. “These accomplishments reflect steady execution against our core strategy: to harness the immense power of genome editing, both for in vivo and ex vivo applications. As we look ahead, our highest priority will be to prepare for the initiation of global pivotal trials for our investigational in vivo CRISPR-based therapy NTLA-2002 for HAE. As this program continue to progress, we believe we are moving closer to setting a new standard of care for people living with HAE and other serious diseases. In addition, we are advancing the next wave of platform capabilities, such as in vivo gene insertion and our proprietary allogeneic solution. Importantly, while the possibilities to apply our industry-leading genome editing technology are expansive, we are taking a disciplined approach with our portfolio by deploying resources on high-impact opportunities and collaborating with a network of other scientific leaders to expand the applications of our innovative technologies.”
Based on the strategic priorities, which will be the Company’s focus over the next two years, Intellia anticipates to initiate Phase 2 portion of the ongoing NTLA-2002 Phase 1/2 study in 1H 2023, to submit an IND in 1H 2023 to support the inclusion of U.S. sites in the Phase 2 study of NTLA-2002, and to present additional clinical data from the ongoing first-in-human study of NTLA-2002 in 2023.